Epoetin alfa for treatment of anemia in HIV-infected patients: Past, present, and future

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue 2, 2004, Pages 1221-1227

  Henry, David H ^a   Volberding, Paul A ^b   Leitz, Gerhard ^c  

^a PENNSYLVANIA HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Ortho Biotech Products LP   (United States)

Author keywords

Anemia; Epoetin alfa; HIV

Indexed keywords

CD4 ANTIGEN; CYTOKINE; ERYTHROPOIETIN; INTERFERON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; ZIDOVUDINE;

ANEMIA; BONE MARROW SUPPRESSION; CELL COUNT; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROPOIESIS; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; NEUROPROTECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SURVIVAL; TREATMENT OUTCOME;

ANEMIA; EPOETIN ALFA; HEMATINICS; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 4644230789     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000135957.03791.ee     Document Type: Review

References (55)

1. Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;2:1175-1178.
2. Bommer J, Kugel M, Schoeppe W, et al. Dose-related effects of recombinant human erythropoietin on erythropoiesis: results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol. 1988;66:85-93.
3. Eschbach JW, Downing MR, Egrie JC, et al. USA multicenter clinical trial with recombinant human erythropoietin (Amgen): results in hemodialysis patients. Contrib Nephrol. 1989;76:160-165.
4. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 1990;322:1488-1493.
5. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Ann Intern Med. 1992;117:739-748.
6. Spivak JL, Barnes DC, Fuchs E, et al. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA. 1989;261:3104-3107.
7. Groopman JE. Management of hematologic complications of human immunodeficiency virus infection. Rev Infect Dis. 1990;12:931-937.
8. Mir N, Costello C, Luckit J, et al. HIV-disease and bone marrow changes: a study of 60 cases. Eur J Haematol 1989;42:339-343.
9. Frontiera M, Myers AM. Peripheral blood and bone marrow abnormalities in the acquired immunodeficiency syndrome. West J Med. 1987;147:157-160.
10. Zon LI, Arkin C, Groopman JE. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol. 1987;66:251-256.
11. Semba RD, Shah N, Klein RS, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDS. 2001;15:473-480.
12. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:315-319.
13. Servais J, Nkoghe D, Schmit JC, et al. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:221-225.
14. Levine AM, Berhane K, Masri-Lavine L, et al. Impact of anemia on the survival of HIV infected women [abstract 2091]. Blood. 2001;98:501a.
15. Sharp V, Paredes J, Steinbock C. Anemia in HIV in the HAART era: is it common [abstract 3179]? Blood. 1999;94(suppl 1):8b.
16. Moore RD, Keruly JC, Chaisson RE. Improved survival with correction of anemia in HIV disease [abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1999.
17. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS. 1999;13:943-950.
18. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:54-57.
19. Creagh T, Mildvan D, the Anemia Study Group. Greater prevalence of anemia in women and African Americans with HIV/AIDS in the HAART era: a study of 10,000 patients. 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, IL, 2002.
20. Lundgren JD, Mocroft A, Gatelli JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA Study. J Infect Dis. 2002;185:178-187.
21. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. Blood. 1998;91:301-308.
22. Volberding P, for The Anemia in HIV Working Group. Consensus statement: anemia in HIV infection - current trends, treatment options, and practice strategies. Clin Ther. 2000;22:1004-1020.
23. Breitbart W, McDonald MV, Rosenfeld B, et al. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage. 1998;15:159-167.
24. Groopman JE. Fatigue in cancer and HIV/AIDS. Oncology (Huntingt). 1998;12:335-344.
25. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Neurology. 1993;43:2245-2252.
26. Revicki DA, Brown RD, Henry DH, et al. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr. 1994;7:474-484.
27. Saag MS, Levine AM, Leitz GJ, et al. Once-weekly epoetin alfa increases hemoglobin and improves quality of life in anemic HIV+ patients. 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, 2001.
28. Grossman H, Bowers B, Leitz G. Once-weekly epoetin alfa (PROCRIT®) corrects hemoglobin and improves quality of life as effectively as three-times-weekly dosing in HIV+ patients [abstract]. 14th International AIDS Conference, Barcelona, 2002.
29. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int J STD AIDS. 2000;11:659-665.
30. Peterman AH, Cella D, Mo F. et al. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1997;6:572-584.
31. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr. 1998;19:29-33.
32. Levine AM, Deyton L, Saag M. Once-weekly dosing of epoetin alfa increases hemoglobin and quality of life in HIV-positive women with anemia. National Conference for Women in HIV/AIDS, Los Angeles, CA, 1999.
33. Levine AM, Deyton L, Saag M. Weekly dosing with epoetin alfa in HIV-infected patients with anemia: interim data [abstract]. 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
34. Saag MS, Levine AM, Deyton L. Once-weekly dosing of epoetin alfa increases hemoglobin and quality of life in HIV-positive patients with anemia [abstract]. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 1999.
35. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 2002;16:813-828.
36. Sulkowski M, Wasserman R, Brau N, et al. Once-weekly recombinant human erythropoietin (epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus-infected patients receiving interferon-α-2b (IFN/RBV) therapy. Hepatitis Single-Topic Conference (AASLD), Chicago, IL, 2001.
37. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2A (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. 37th Annual Meeting of the European Association for the Study of the Liver, Madrid, 2002.
38. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response to genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
39. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. Stem Cells. 2002;20:485-492.
40. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999;19:643-651.
41. Sasaki R, Masuda S, Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci. 2001;16:110-113.
42. Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opin Hematol. 2002;9:93-100.
43. Drew WL, Hardy WD. Management of cytomegalovirus disease in AIDS. Available at: http://hivinsite.ucsf.edu. Accessed March 19, 2003.
44. Raina J, Bainbridge JW, Shah SM. Decreased visual acuity in patients with cytomegalovirus retinitis and AIDS. Eye. 2000;14:8-12.
45. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002;8:718-724.
46. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2002;99:10659-10664.
47. Sirén A-L, Ehrenreich H. Erythropoietin - a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci. 2001;251:179-184.
48. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signalling is required for normal brain development. Development. 2002;129:505-516.
49. Ruscher K., Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.
50. Cerami A, Brines ML, Ghezzi P, et al. Effects of epoetin alfa on the central nervous system. Semin Oncol. 2001;28:66-70.
51. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA. 2002;99:9450-9455.
52. Sirén A-L, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98:4044-4049.
53. Springborg JB, Ma XD, Rochat P, et al. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after sub-arachnoid haemorrhage in rats. Br J Pharmacol. 2002;135:823-829.
54. Keswani S, Polley M, Leitz G, et al. Erythropoietin is neuroprotective in in vitro models of HIV neuropathy [abstract]. 11th CROI, San Francisco, CA, February 8-11, 2004.
55. Wu SC, Lin SL, Jeng FR. Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients. Scand J Urol Nephrol. 2001;35:136-140.